Brauns / iStock
Health insurer Aetna and New Jersey-based diagnostic test company Interpace have signed a new national agreement for thyroid tests.
The contract includes Interpace’s ThyGenX and ThyraMIR molecular tests for indeterminate thyroid nodules.
Aetna, the third largest health plan in the US with over 44.9 million members nationwide, began covering ThyGenX in June 2015 and ThyraMIR in November 2016.
Following the agreement that goes into effect mid-August 2017, Interpace will become a part of Aetna’s laboratory network for selected services.
"The agreement with Aetna is another significant reimbursement milestone demonstrating our ability to convert our product coverage approvals with major insurance providers into successful contractual agreements," said Jack Stover, Interpace’s president and CEO. "Coverage of our thyroid products has continued to increase and improve over the past few quarters and now totals over 250 million covered lives."
The company noted that the agreement covers many of Aetna’s products, including commercial and Medicare Advantage plans. It does not include Medicaid, auto insurance, or workman’s compensation products.
Aetna, Interpace Diagnostics, Agreement, Health insurance, Thyroid tests, US
